News & Updates
Filter by Specialty:

SGLT2 inhibitors potentially protective against dry eye disease
Type 2 diabetes (T2D) patients on sodium-glucose cotransporter 2 (SGLT2) inhibitors appear to be at lower risk of dry eye disease (DED) compared with their counterparts who are receiving glucagonlike peptide-1 receptor agonists (GLP-1 RAs), as shown in a study.
SGLT2 inhibitors potentially protective against dry eye disease
29 Sep 2022
Vision impairment tied to depression, anxiety in children
Children with vision impairment are at higher risk of developing symptoms of depression and anxiety, according to a study, noting that surgical treatment of strabismus may improve these symptoms.
Vision impairment tied to depression, anxiety in children
28 Sep 2022
Regular coffee intake ups risk of primary open-angle glaucoma
Genetic evidence from a recent study suggests that habitual coffee drinkers have an increased risk of primary open-angle glaucoma (POAG).
Regular coffee intake ups risk of primary open-angle glaucoma
06 Sep 2022
Brolucizumab noninferior to aflibercept in nAMD
Treatment with brolucizumab 6 mg, dosed every 4 weeks, is not inferior to aflibercept 2 mg, dosed every 4 weeks, in previously treated participants with neovascular age-related macular degeneration (nAMD) and persistent retinal fluid, a study has shown.
Brolucizumab noninferior to aflibercept in nAMD
03 Sep 2022
Do eyeglasses act as a shield against SARS-CoV-2 infection? Maybe—or maybe not
There is inconclusive evidence that wearing one’s eyeglasses can lower their chances of contracting COVID-19, according to a recent study.